Gideon Gil

Research on Covid-19 dominates the bracket for this year’s #STATMadness, our annual competition in which readers choose the most important biomedical advance or discovery to emerge from U.S. labs in the past year.

While it remains fairly unusual for hospital chiefs across the country to work as directors for publicly traded companies, the practice is now routine in Boston.

STAT’s Gideon Gil sits down with Dr. Allison Bond of the University of California, San Francisco, to discuss Covid-19 long-haulers.

The first recipient of the Sharon Begley-STAT Science Reporting Fellowship is Isabella Cueto, a Cuban American journalist who has worked as a reporter in Florida, South Carolina, and California.

The procedure aims to restore proprioception, the ability to sense where our limbs are in space and how fast and forcefully they’re moving.

If the first week of proceedings in the Elizabeth Holmes trial drew the battle lines, they also made clear it’ll be a very long process.

Hear a researcher from the 2022 STAT Madness winning team discuss their work, its potential impact, and what’s next in their field.

A man with muscular dystrophy who was first in line to receive an experimental CRISPR therapy tailor made to treat the cause of his rare form of the disease has died.

Substandard asparaginase, a drug to fight childhood leukemia, has been shipped to more than 90 countries, overwhelmingly from companies in India.

The dispute with Lander set off a revolution that in 1999 would prompt MIT to publicly acknowledge it had discriminated against women on its faculty.